High-sensitivity C-reactive protein to detect metabolic syndrome in a centrally obese population: A cross-sectional analysis

Cardiovascular Diabetology

Volumn 11, Issue , 2012, Pages

  den Engelsen, Corine ^a   Koekkoek, Paula S ^a   Gorter, Kees J ^a   van den Donk, Maureen ^a   Salomé, Philippe L ^b   Rutten, Guy E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Locatie't Steyn ^*  (Netherlands)

Author keywords

Abdominal obesity; High sensitivity C reactive protein; Metabolic syndrome; Screening

Indexed keywords

ALCOHOL; C REACTIVE PROTEIN; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ABDOMINAL OBESITY; ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; CALCULATION; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PHYSICAL EXAMINATION; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SMOKING; BLOOD; METABOLISM; MIDDLE AGED; NETHERLANDS; OUTCOME ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL;

ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LINEAR MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NETHERLANDS; OBESITY, ABDOMINAL; OUTCOME ASSESSMENT (HEALTH CARE); RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 84858020065     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-11-25     Document Type: Article

References (33)

1. Sattar N, McConnachie A, Shaper AG, Blauw GJ, Buckley BM, de Craen AJ, Ford I, Forouhi NG, Freeman DJ, Jukema JW, Lennon L, Macfarlane PW, Murphy MB, Packard CJ, Stott DJ, Westendorp RG, Whincup PH, Shepherd J, Wannamethee SG. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 2008, 371:1927-1935. 10.1016/S0140-6736(08)60602-9, 18501419.
2. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, O'Reilly DS, Packard CJ, Sattar N. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002, 51:1596-1600. 10.2337/diabetes.51.5.1596, 11978661.
3. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836-843. 10.1056/NEJM200003233421202, 10733371.
4. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999, 138:S419-S420. 10.1016/S0002-8703(99)70266-8, 10539839.
5. Ilanne-Parikka P, Eriksson JG, Lindstrom J, Peltonen M, Aunola S, Hamalainen H, Keinanen-Kiukaanniemi S, Laakso M, Valle TT, Lahtela J, Uusitupa M, Tuomilehto J. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care 2008, 31:805-807. 10.2337/dc07-1117, 18184907.
6. Wong ND, Pio JR, Franklin SS, L'Italien GJ, Kamath TV, Williams GR. Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome. Am J Cardiol 2003, 91:1421-1426. 10.1016/S0002-9149(03)00392-8, 12804727.
7. Van den Donk M, Bobbink IWG, Gorter KJ, Salomé PL, Rutten GEHM. Identifying people with metabolic syndrome in primary care by screening with a mailed tape measure. A survey of 14,000 people in the Netherlands. Prev Med 2009, 48:345-350. 10.1016/j.ypmed.2009.02.004, 19463483.
8. Pataky Z, Bobbioni-Harsch E, Golay A. Open questions about metabolically normal obesity. Int J Obes (Lond) 2010, 34(Suppl 2):S18-S23.
9. Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J, Sowers MR. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med 2008, 168:1617-1624. 10.1001/archinte.168.15.1617, 18695075.
10. Wendel-Vos GC, Schuit AJ, Saris WH, Kromhout D. Reproducibility and relative validity of the short questionnaire to assess health-enhancing physical activity. J Clin Epidemiol 2003, 56:1163-1169. 10.1016/S0895-4356(03)00220-8, 14680666.
11. Kemper HGC, Ooijendijk WTM, Stiggelbout M. Consensus over de Nederlandse Norm voor Gezond Bewegen. Tijdschrift voor Sociale Gezondheidszorg 2000, 78:180-183.
12. Stalman WA, Scheltens T, Burgers JS, Hukkelhoven CW, Smorenburg SM, Banga JD, Dippel DW. NHG-Standaard Cardiovasculair risicomanagement 2006, Houten: Bohn Stafleu van Loghum.
13. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645. 10.1161/CIRCULATIONAHA.109.192644, 19805654.
14. Taubert K, Tracy RP, Vinicor F, Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499-511. 10.1161/01.CIR.0000052939.59093.45, 12551878.
15. Morley JJ, Kushner I. Serum C-reactive protein levels in disease. Ann N Y Acad Sci 1982, 389:406-418. 10.1111/j.1749-6632.1982.tb22153.x, 6953917.
16. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 1997, 43:52-58.
17. Dupuy AM, Jaussent I, Lacroux A, Durant R, Cristol JP, Delcourt C. Waist circumference adds to the variance in plasma C-reactive protein levels in elderly patients with metabolic syndrome. Gerontology 2007, 53:329-339. 10.1159/000103555, 17551260.
18. Santos AC, Lopes C, Guimaraes JT, Barros H. Central obesity as a major determinant of increased high-sensitivity C-reactive protein in metabolic syndrome. Int J Obes (Lond) 2005, 29:1452-1456.
19. Zuliani G, Volpato S, Galvani M, Ble A, Bandinelli S, Corsi AM, Lauretani F, Maggio M, Guralnik JM, Fellin R, Ferrucci L. Elevated C-reactive protein levels and metabolic syndrome in the elderly: The role of central obesity data from the InChianti study. Atherosclerosis 2009, 203:626-632. 10.1016/j.atherosclerosis.2008.07.038, 2710530, 18845301.
20. Florez H, Castillo-Florez S, Mendez A, Casanova-Romero P, Larreal-Urdaneta C, Lee D, Goldberg R. C-reactive protein is elevated in obese patients with the metabolic syndrome. Diabetes Res Clin Pract 2006, 71:92-100. 10.1016/j.diabres.2005.05.003, 16002176.
21. Gonzalez AS, Guerrero DB, Soto MB, Diaz SP, Martinez-Olmos M, Vidal O. Metabolic syndrome, insulin resistance and the inflammation markers C-reactive protein and ferritin. Eur J Clin Nutr 2006, 60:802-809. 10.1038/sj.ejcn.1602384, 16493453.
22. Kressel G, Trunz B, Bub A, Hulsmann O, Wolters M, Lichtinghagen R, Stichtenoth DO, Hahn A. Systemic and vascular markers of inflammation in relation to metabolic syndrome and insulin resistance in adults with elevated atherosclerosis risk. Atherosclerosis 2009, 202:263-271. 10.1016/j.atherosclerosis.2008.04.012, 18501910.
23. Lee WY, Park JS, Noh SY, Rhee EJ, Sung KC, Kim BS, Kang JH, Kim SW, Lee MH, Park JR. C-reactive protein concentrations are related to insulin resistance and metabolic syndrome as defined by the ATP III report. Int J Cardiol 2004, 97:101-106. 10.1016/j.ijcard.2003.08.016, 15336815.
24. Kawamoto R, Tabara Y, Kohara K, Miki T, Kusunoki T, Takayama S, Abe M, Katoh T, Ohtsuka N. High-sensitivity C-reactive protein and gamma-glutamyl transferase levels are synergistically associated with metabolic syndrome in community-dwelling persons. Cardiovasc Diabetol 2010, 9:87. 10.1186/1475-2840-9-87, 3014885, 21143879.
25. Mahajan A, Jaiswal A, Tabassum R, Podder A, Ghosh S, Madhu SV, Mathur SK, Tandon N, Bharadwaj D. Elevated levels of C-reactive protein as a risk factor for Metabolic Syndrome in Indians. Atherosclerosis 2012, 220:275-281. 10.1016/j.atherosclerosis.2011.10.031, 22104116.
26. Aronson D, Bartha P, Zinder O, Kerner A, Markiewicz W, Avizohar O, Brook GJ, Levy Y. Obesity is the major determinant of elevated C-reactive protein in subjects with the metabolic syndrome. Int J Obes Relat Metab Disord 2004, 28:674-679. 10.1038/sj.ijo.0802609, 14993913.
27. Frohlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H, Muche R, Brenner H, Koenig W. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 2000, 23:1835-1839. 10.2337/diacare.23.12.1835, 11128362.
28. Lu B, Yang Y, Yang Z, Feng X, Wang X, Zhang Z, Hu R. Insulin resistance in Chinese patients with type 2 diabetes is associated with C-reactive protein independent of abdominal obesity. Cardiovasc Diabetol 2010, 9:92. 10.1186/1475-2840-9-92, 3020174, 21167068.
29. Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, Okamoto Y, Ohashi K, Nagaretani H, Kishida K, Nishizawa H, Maeda N, Kobayashi H, Hiraoka H, Matsuzawa Y. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003, 107:671-674. 10.1161/01.CIR.0000055188.83694.B3, 12578865.
30. Bouchard L, Tchernof A, Deshaies Y, Marceau S, Lescelleur O, Biron S, Vohl MC. ZFP36: a promising candidate gene for obesity-related metabolic complications identified by converging genomics. Obes Surg 2007, 17:372-382. 10.1007/s11695-007-9067-5, 17546847.
31. Faucher G, Guenard F, Bouchard L, Garneau V, Turcot V, Houde A, Tchernof A, Bergeron J, Deshaies Y, Hould FS, Lebel S, Marceau P, Vohl MC. Genetic contribution to C-reactive protein levels in severe obesity. Mol Genet Metab 2011,
32. Niehoff AG, van Haeften TW, Onland-Moret NC, Elbers CC, Wijmenga C, van der Schouw YT. C-reactive protein is independently associated with glucose but not with insulin resistance in healthy men. Diabetes Care 2007, 30:1627-1629. 10.2337/dc06-2531, 17372148.
33. Janssen PG, Gorter KJ, Stolk RP, Rutten GE. Low yield of population-based screening for Type 2 diabetes in the Netherlands: the ADDITION Netherlands study. Fam Pract 2007, 24:555-561. 10.1093/fampra/cmm052, 17962235.